SCHEMBL3230611

SCHEMBL3230611

O=C(CN1CCN(C(=O)O)CC1)Nc1nc2cc(F)c(Sc3cnc4ncccn34)cc2s1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SLC27A1 Q6PCB7 1/20 0.40
CLK1 P49759 2/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PIK3CA P42336 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540218 0.93 USP2 (0.41) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2547142 0.93 USP2 (0.42) USP2LMNATSHRSMN1; SMN2CLK1
SCHEMBL2540214 0.91 USP2 (0.40) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2543731 0.90 USP2 (0.39) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2541916 0.90 USP2 (0.39) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2539010 0.90 CLK1 (0.47) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2538982 0.90 USP2 (0.40) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2546149 0.90 LMNA (0.39) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2543264 0.90 USP2 (0.40) USP2LMNATSHRSMN1; SMN2SLC27A1
SCHEMBL2547871 0.89 ALDH1A1 (0.44) USP2LMNATSHRSMN1; SMN2SLC27A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010007318-A2 NOVEL IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS SANOFI-AVENTIS (FR) 2010-01-21 WO disclosed